194 related articles for article (PubMed ID: 2459370)
21. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
[TBL] [Abstract][Full Text] [Related]
22. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
Preston KL; Bigelow GE
J Pharmacol Exp Ther; 1993 Feb; 264(2):813-23. PubMed ID: 7679737
[TBL] [Abstract][Full Text] [Related]
23. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
[TBL] [Abstract][Full Text] [Related]
24. Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats.
Comer SD; Lac ST; Curtis LK; Carroll ME
J Pharmacol Exp Ther; 1993 Dec; 267(3):1470-7. PubMed ID: 7903391
[TBL] [Abstract][Full Text] [Related]
25. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
Preston KL; Bigelow GE
J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
[TBL] [Abstract][Full Text] [Related]
26. The effects of buprenorphine in buprenorphine-maintained volunteers.
Strain EC; Walsh SL; Preston KL; Liebson IA; Bigelow GE
Psychopharmacology (Berl); 1997 Feb; 129(4):329-38. PubMed ID: 9085402
[TBL] [Abstract][Full Text] [Related]
27. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
[TBL] [Abstract][Full Text] [Related]
28. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
White DA; Holtzman SG
J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
[TBL] [Abstract][Full Text] [Related]
30. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans.
Rush CR
Alcohol Clin Exp Res; 2001 Jan; 25(1):9-17. PubMed ID: 11198720
[TBL] [Abstract][Full Text] [Related]
32. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
33. Naltrexone-buprenorphine interactions: effects on cocaine self-administration.
Mello NK; Lukas SE; Mendelson JH; Drieze J
Neuropsychopharmacology; 1993 Nov; 9(3):211-24. PubMed ID: 8280345
[TBL] [Abstract][Full Text] [Related]
34. Physiological and subjective effects of hydromorphone in postaddict volunteers.
McCaul M; Stitzer M; Bigelow G; Liebson I
NIDA Res Monogr; 1982 Apr; 41():301-8. PubMed ID: 6181412
[No Abstract] [Full Text] [Related]
35. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
[TBL] [Abstract][Full Text] [Related]
36. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.
Bigelow GE; Preston KL; Schmittner J; Dong Q; Gastfriend DR
Drug Alcohol Depend; 2012 Jun; 123(1-3):57-65. PubMed ID: 22079773
[TBL] [Abstract][Full Text] [Related]
37. Buprenorphine and naloxone alone and in combination in opioid-dependent humans.
Preston KL; Bigelow GE; Liebson IA
Psychopharmacology (Berl); 1988; 94(4):484-90. PubMed ID: 2453895
[TBL] [Abstract][Full Text] [Related]
38. The effect of buprenorphine and benzodiazepines on respiration in the rat.
Nielsen S; Taylor DA
Drug Alcohol Depend; 2005 Jul; 79(1):95-101. PubMed ID: 15943948
[TBL] [Abstract][Full Text] [Related]
39. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
Foltin RW; Fischman MW
J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
[TBL] [Abstract][Full Text] [Related]
40. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
Petry NM; Bickel WK; Badger GJ
Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
